All News
SLE Conference Preview: progress in biologics
The pharmacology treatment including biologics, cellular-based therapies, and Bi-specific T-cell Engager (BiTE) in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the physicians.
Read Article
This retrospective cohort analysis by Dr. Lihi Eder et al showed that among patients with PsA, those w/ high dse activity & high 3VAS scores were assoc w/⬆️ risk of atrial tachyarrythmias.
Main message: PsA conveys ⬆️CV risk; inflamm control is key!
#ACR25 @RheumNow Abs0522 https://t.co/7sRM7K4V1c
sheila RHEUMarampa ( View Tweet)
In a nationally representative NHANES sample, inflammatory back pain (IBP) was not associated with HLA-B27 positivity or elevated CRP, regardless of IBP criteria used (e.g., Berlin 8a: OR 0.88, p=0.876). IBP alone may be insufficient for identifying axSpA-related immunogenetic or https://t.co/82NjVU171z
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
What can we learn from longitudinal peripheral blood multi-omic profiling in at-risk individuals?
50 RA converters vs. non converters from StopRA study
Decision tree showing highest risk for conversion to clinical RA in Individuals w/
-CCP3 ≥108 units
-T peripheral helpers https://t.co/jw53EB6tI6
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#0774
Multi-omic profiling of anti-CCP3+ “at-risk” individuals reveals Tph & cytotoxic CD8+ expansions, altered gene/chromatin profiles and predictive model (AUC 0.77) for RA conversion
PTPN22 locus accessibility & Tph ≥ 2.45% identify highest risk. @RheumNow #ACR25 https://t.co/JDSMkdmoGv
Mrinalini Dey DrMiniDey ( View Tweet)
Not just for salivary glands—lacrimal ultrasound helps too.
In early Sjögren’s, lacrimal + salivary US clearly distinguished SjD from sicca (AUC up to 0.97).
Noninvasive, reproducible, and highly diagnostic.
@RheumNow #ACR25 Abstract #0507
Jiha Lee JihaRheum ( View Tweet)
A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies!
Japanese study
MDA5 (201-300) positivity associated w/
Lower 6-month progression-free survival (43% vs. 74%)
Lower 5-year survival rates (34% vs. 66%)
Validation in other populations awaited https://t.co/IBiYyATer4
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. Werth on the #SLE guidelines on tx of cutaneous LE:
🔅All patients should be on hydroxychloroquine unless with CI.
☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE.
#ACR25 @RheumNow https://t.co/ok5jAi7uO0
Links:
sheila RHEUMarampa ( View Tweet)
Getting down with Jack at the @RheumNow #ACR25 stand - come and say hello!
(and Ask Cush Anything - scan the QR code, and maybe end up on the podcast!) https://t.co/0u0boHIIR3
David Liew drdavidliew ( View Tweet)
#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Please find my article on conference preview @RheumNow
https://t.co/usIXPsj5bm https://t.co/4wmWvDyv83
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Come to our first #HealthLiteracy poster of #ACR25!
#0190
Cluster analysis >900 people with IA
Lowest health literacy cluster assoc w:
4× ⬆️anxiety/depression
2× ⬆️disease activity, vs highest HL
Higher HL assoc w older age & ⬆️comorbidities but fewer mental health Sx
@RheumNow https://t.co/iIRXaOl4qZ
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
How does cMRI change over time in cardiac EGPA?
Cheng et al. retrospectively reviewed:
- 11 EGPA pt with LGE on initial cMRI
Despite treatment:
- 10/11 persistent LGE on 2nd cMRI
- 4/4 on 3rd
- 2/2 on 4th
Unclear use as a monitor of tx response
@RheumNow #ACR25
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
#0773 Anti-MDA5 epitope mapping identifies key regions (aa 201-300, 601-700) linked to treatment resistance & poor prognosis in DM-ILD and even IIPs.
Epitope-specific antibodies could refine risk stratification & guide therapy in ILD beyond autoimmune disease. @RheumNow #ACR25 https://t.co/moRffVGZPn
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognostic (Non-White, active serology or active sediment)
- 71% had LN (No class IV or Mixed)
- 46% actionable LN
Cost-effectiveness data needed.
#ACRBest @RheumNow https://t.co/Bt3fuA3aJh
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ilKWG8CQbe
Dr M Nazibur Rahman, MD (Rheumatology) NaziburM ( View Tweet)
AI-enhanced MRI integrating STIR and T1-weighted MRI with BME data reflecting both inflammatory and structural changes, enabling the AI model to predict clinical diagnoses of axSpA with accuracy of 82%. Successfully identified axSpA patients who did not meet the ASAS criteria for https://t.co/dLlGj0ZFpj
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Join us at 5pm CST for Day 1 #ACR25 recap! https://t.co/EwZSiPhysF
Dr. John Cush RheumNow ( View Tweet)
Plenary session at #ACR25!
#0772 When should we biopsy in SLE?
In pts with uPCR 0.25-0.49 g/g + LN predictors, 69% already had LN (many Class III/V). Low C3/C4 were most important factors.
0.5 g/g cutoff may delay diagnosis and treatment. Time to rethink thresholds? @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#LLM can be #virtual #tutor for
👇
#OSCE
RCT - better competence &confidence
#AI & #medical #education
AI trained to #tutor
Also grading OSCE #AI + human
@RheumNow @ACRheum #26S17 https://t.co/CzKoxyjpY8
Janet Pope Janetbirdope ( View Tweet)
Early, low level proteinuria is a harbinger in SLE. ~50% with elevated UPCR but <0.5 had actionable LN on early bx.
Risk factor = low c3/c4
Urine biomarkers promising
#ACRBest #ACR25 @RheumNow https://t.co/WuNPKeqeid
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
